US2004162327A1PendingUtilityA1
Crystalline form of telmisartan sodium
Assignee: BOEHRINGER INGELHEIM PHARMAPriority: Oct 31, 2001Filed: Feb 12, 2004Published: Aug 19, 2004
Est. expiryOct 31, 2021(expired)· nominal 20-yr term from priority
C07D 235/20
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of formula 2
wherein H—X denotes an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, toluenesulphonic acid and methanesulphonic acid.
2 . The compound of formula 2 according to claim 1 , wherein H—X denotes hydrogen chloride.
3 . A compound according to claim 1 or claim 2 , in crystalline form.Join the waitlist — get patent alerts
Track US2004162327A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.